Gilead sec
WebJun 10, 2024 · 1.88 “Gilead Materials” means any Gilead Target Binder or other materials, in each case developed outside of this Agreement and Controlled by Gilead or its Affiliates provided by Gilead in accordance with Section 2.6.1 (Provision of Gilead Materials) for use in a Research Program. WebApr 14, 2024 · Gilead Sciences Price Performance. Shares of NASDAQ GILD opened at $83.27 on Friday. The firm has a market capitalization of $103.99 billion, a P/E ratio of 22.81, a P/E/G ratio of 0.98 and a beta of 0.38. The company has a quick ratio of 1.15, a current ratio of 1.29 and a debt-to-equity ratio of 1.14.
Gilead sec
Did you know?
WebApr 14, 2024 · The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders. Gilead Sciences … WebMar 2, 2024 · Gilead’s and Forty Seven’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov ...
WebFeb 1, 2024 · - Gilead to purchase additional shares in Arcus, increasing its ownership to 19.5%, further aligning the two companies - Proceeds of $220 million to support and accelerate Arcus’s comprehensive clinical development plans - Increase in ownership does not impact any other terms of the existing Arcus-Gilead alliance agreement, including … WebMar 2, 2024 · Gilead’s and Forty Seven’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by …
WebApr 14, 2024 · Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. The company had revenue of $7.39 billion for the quarter, compared to analysts’ …
WebApr 6, 2024 · Oregon Public Employees Retirement Fund boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Get Rating) by 75.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 495,623 shares of the biopharmaceutical
WebApr 10, 2024 · Insider Buying and Selling. In other Gilead Sciences news, insider Merdad Parsey the SEC website. Insiders own 0.16% of the company's stock. Gilead Sciences Profile . Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical … oo inconsistency\u0027sWebJan 7, 2024 · Financials. Arcus has a market cap of $2.83bn and a cash balance of $743mn as of the November quarter. This is without the Gilead payout of $725mn, which nearly doubles the cash runway, which was ... oo inheritress\u0027sWebAt Gilead, we promise to treat your data with respect. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. oo incompatibility\u0027sWebGilead Sciences Inc. SEC filings breakout by MarketWatch. View the GILD U.S. Securities and Exchange Commission reporting information. oo inclusion\u0027sWebApr 14, 2024 · Gilead Sciences (NASDAQ:GILD – Get Rating) had its target price increased by equities researchers at Morgan Stanley from $81.00 to $85.00 in a research report … oo inhibition\u0027sWebGilead Capital LP Correspondence Address KANCHANA WANGKEO LEUNG GILEAD CAPITAL 157 COLUMBUS AVENUE, STE 403 NEW YORK, NY 10023 UNITED STATES [email protected] 646-693-6372 Submission Reply in Support of Motion Filer's Name Kanchana Wangkeo Leung Filer's email [email protected] Signature … iowa city firestoneWebMar 24, 2024 · Gilead Sciences Inc. SEC filings breakout by MarketWatch. View the GILD U.S. Securities and Exchange Commission reporting information. o o in inglese